A nonprofit group called the Medicines Patent Pool has had licensing rights to the drug for the last five years. The deal was criticized for being too restrictive, as high-income countries were denied access to the drug, according to STAT.
Since Kaltera has shown to be somewhat effective in treating COVID-19, AbbVie said it would dedicate the intellectual property rights for the drug to the public.
“The big win here may be for people for HIV. Access to [Kaltera] has been a battle for years,” Ellen ‘t Hoen, a senior researcher in the global health unit at the University of Groningen in the Netherlands, told STAT.
Read the full article here.
More articles on pharmacy:
CVS Health recruiting 50,000 workers amid COVID-19 pandemic
69 experimental COVID-19 drugs, treatments identified
Physicians found hoarding experimental COVID-19 treatments for relatives, report says
